AR084169A1 - COMBINATION THAT INCLUDES A FAMILY DERIVATIVE OF COMBRETASTATINAS AND CETUXIMAB - Google Patents
COMBINATION THAT INCLUDES A FAMILY DERIVATIVE OF COMBRETASTATINAS AND CETUXIMABInfo
- Publication number
- AR084169A1 AR084169A1 ARP110104553A ARP110104553A AR084169A1 AR 084169 A1 AR084169 A1 AR 084169A1 AR P110104553 A ARP110104553 A AR P110104553A AR P110104553 A ARP110104553 A AR P110104553A AR 084169 A1 AR084169 A1 AR 084169A1
- Authority
- AR
- Argentina
- Prior art keywords
- cetuximab
- combination
- combretastatinas
- family derivative
- family
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Combinación farmacéutica que comprende un derivado de la familia de las combretastatinas, tal como la ombrabulina, que puede estar en forma de base o en forma de una sal farmacéuticamente aceptable, y cetuximab.Reivindicación 2: Combinación según la reivindicación 1 en la que el derivado de la familia de las combretastatinas es AVE8062 de fórmula (1), que puede estar en forma de base o en forma de sal farmacéuticamente aceptable.Pharmaceutical combination comprising a derivative of the family of combretastatins, such as ombrabulin, which may be in the form of a base or in the form of a pharmaceutically acceptable salt, and cetuximab. Claim 2: Combination according to claim 1 wherein the derivative of the family of combretastatins is AVE8062 of formula (1), which may be in the form of a base or in the form of a pharmaceutically acceptable salt.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1060293A FR2968557A1 (en) | 2010-12-09 | 2010-12-09 | ANTITUMOR COMBINATION COMPRISING A DRIFT OF THE COMBRETASTATIN FAMILY AND THE CETUXIMAB |
Publications (1)
Publication Number | Publication Date |
---|---|
AR084169A1 true AR084169A1 (en) | 2013-04-24 |
Family
ID=43837735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110104553A AR084169A1 (en) | 2010-12-09 | 2011-12-06 | COMBINATION THAT INCLUDES A FAMILY DERIVATIVE OF COMBRETASTATINAS AND CETUXIMAB |
Country Status (5)
Country | Link |
---|---|
AR (1) | AR084169A1 (en) |
FR (1) | FR2968557A1 (en) |
TW (1) | TW201306833A (en) |
UY (1) | UY33789A (en) |
WO (1) | WO2012076688A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014066606A2 (en) * | 2012-10-25 | 2014-05-01 | Glaxosmithkline Llc | Combination |
US20170128592A1 (en) * | 2015-10-01 | 2017-05-11 | Indian Institute Of Technology, Bombay | Targeted polymeric nano-complexes as drug delivery system |
CN112225673B (en) * | 2020-11-13 | 2022-08-02 | 义乌市华耀医药科技有限公司 | Amino combretastatin derivative and application thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4996237A (en) | 1987-01-06 | 1991-02-26 | Arizona Board Of Regents | Combretastatin A-4 |
TW325458B (en) | 1993-09-08 | 1998-01-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer |
US5731353A (en) | 1993-09-08 | 1998-03-24 | Ajinomoto Co., Inc. | Stilbene derivatives and pharmaceutical compositions containing them |
TW334418B (en) | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
AU747599C (en) | 1998-04-03 | 2003-06-05 | Ajinomoto Co., Inc. | Antitumor agents |
US20020183266A1 (en) | 2001-03-15 | 2002-12-05 | Aventis Pharma, S.A. | Combination comprising combretastatin and anticancer agents |
WO2003000290A1 (en) | 2001-06-25 | 2003-01-03 | Ajinomoto Co., Inc. | Antitumor agents |
FR2838437B1 (en) | 2002-04-11 | 2004-06-04 | Aventis Pharma Sa | PROCESSES FOR THE PREPARATION OF COMBRETASTATINS |
GB0410817D0 (en) * | 2004-05-14 | 2004-06-16 | Angiogene Pharm Ltd | Vascular damaging therapy |
FR2895258B1 (en) | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | COMBINATION COMPRISING COMBRETASTATIN AND ANTICANCER AGENTS |
AU2008335469A1 (en) * | 2007-12-13 | 2009-06-18 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
US20090209496A1 (en) * | 2008-02-15 | 2009-08-20 | David Chaplin | Methods and compositions for enhancing the efficacy of rtk inhibitors |
FR2945210B1 (en) * | 2009-05-07 | 2011-07-01 | Sanofi Aventis | ANTITUMOR COMBINATION COMPRISING AVE8062 AND SORAFENIB |
-
2010
- 2010-12-09 FR FR1060293A patent/FR2968557A1/en active Pending
-
2011
- 2011-12-06 AR ARP110104553A patent/AR084169A1/en not_active Application Discontinuation
- 2011-12-09 WO PCT/EP2011/072310 patent/WO2012076688A1/en active Application Filing
- 2011-12-09 TW TW100145626A patent/TW201306833A/en unknown
- 2011-12-09 UY UY0001033789A patent/UY33789A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW201306833A (en) | 2013-02-16 |
WO2012076688A1 (en) | 2012-06-14 |
FR2968557A1 (en) | 2012-06-15 |
UY33789A (en) | 2012-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP13013074A (en) | NEW DERIVATIVES OF PIRIDINA | |
AR077629A1 (en) | SMAC MIMETICO | |
UY33183A (en) | INHIBITING COMPOUNDS OF VIRUS FLAVIVIRIDAE, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT | |
CO6430459A2 (en) | PROLIN DERIVATIVES AS CATEPSIN INHIBITORS | |
GT201400012A (en) | INHIBITOR COMPOUND OF THE SIGNALING OF THE NOTCH TRAJECTORY | |
CU20140068A7 (en) | SUBSTITUTED TRIAZOLOPIRIDINS | |
AR090456A1 (en) | PHARMACEUTICAL COMBINATIONS THAT INCLUDE AN ANALOG OF THIONUCLEOTIDES | |
SV2011004019A (en) | 2-ACETAMIDO-5-ARIL-1,2,4-SUBSTITUTED TRIAZOLONS AND ITS USE | |
CR20130560A (en) | BEZOTIAZOL COMPOUNDS AND THEIR PHARMACEUTICAL USE | |
ECSP12012103A (en) | VIRUS FLAVIVIRIDAE INHIBITORS. | |
CO6620055A2 (en) | Certain amino-pyrimidines, compositions thereof and methods for the use thereof | |
CU20140072A7 (en) | DERIVATIVES OF DIHIDRO-OXAZINA AND DIHIDRO-PIRIDO-OXAZINA | |
CR20150250A (en) | NEW DERIVATIVES OF PIRIDINA | |
CR20140134A (en) | PHARMACEUTICAL COMPOSITIONS | |
CR20150204A (en) | NEW DERIVATIVES OF PIRIDINA | |
HN2011003403A (en) | HETEROCICLIC SULFONAMIDS, USES AND PHARMACEUTICAL COMPOSITIONS OF THE SAME | |
CR20110219A (en) | NAPHYLACTIC ACIDS | |
CO6390102A2 (en) | ANITUMORAL COMBINATION INCLUDING AVE8062 AND SORAFENIB | |
UY33794A (en) | DIMERIC INHIBITORS OF THE IAP | |
UY33236A (en) | DIMERIC INHIBITORS OF THE IAP | |
AR090806A1 (en) | GLUCOSIDS OF PIRAZOL AND ITS USE IN THE TREATMENT OF TYPE I AND II DIABETES | |
UY32404A (en) | 4-ARIL-BUTAN-1,3-DIAMIDS | |
AR082215A1 (en) | PHARMACEUTICAL COMPOSITION NICE TO THE PALATE | |
EA201490199A8 (en) | THERAPEUTIC WAYS | |
CL2014001399A1 (en) | Anticoagulant reversion compounds; Pharmaceutical composition and the use thereof to reverse the anticoagulant effect of a coagulation inhibitor. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |